{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:25:40Z","timestamp":1794234340357,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-64730-2","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:15:25Z","timestamp":1787663725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of platelet-to-HDL cholesterol ratio with hyperuricemia among Qatari adults: a national primary care study"],"prefix":"10.1038","volume":"16","author":[{"given":"Melis","family":"Dorter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naela Darwish","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"1","key":"64730_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01916-y","volume":"9","author":"L Du","year":"2024","unstructured":"Du, L. et al. Hyperuricemia and its related diseases: Mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9(1), 212 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"64730_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03427-1","volume":"26","author":"K Guo","year":"1999","unstructured":"Guo, K. et al. Prevalence of and trends in hyperuricemia by race and ethnicity among US adolescents, 1999-2018. Arthritis Res. Ther. 26(1), 193 (1999).","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"64730_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11892-023-01506-2","volume":"23","author":"J Jiang","year":"2023","unstructured":"Jiang, J. et al. Prevalence of diabetes in patients with hyperuricemia and gout: A systematic review and meta-analysis. Curr. Diab. Rep. 23(6), 103\u2013117 (2023).","journal-title":"Curr. Diab. Rep."},{"issue":"8","key":"64730_CR4","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","volume":"6","author":"GBD 2021 Gout Collaborators","year":"2024","unstructured":"GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 6(8), e507\u2013e517 (2024).","journal-title":"Lancet Rheumatol."},{"key":"64730_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep39884","volume":"7","author":"T Braga","year":"2017","unstructured":"Braga, T. et al. Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep. 7, 39884 (2017).","journal-title":"Sci. Rep."},{"issue":"8","key":"64730_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","volume":"95","author":"PJ Barter","year":"2004","unstructured":"Barter, P. J. et al. Antiinflammatory properties of HDL. Circ. Res. 95(8), 764\u2013772 (2004).","journal-title":"Circ. Res."},{"issue":"2","key":"64730_CR7","doi-asserted-by":"publisher","DOI":"10.31083\/RCM26403","volume":"26","author":"Y Huang","year":"2025","unstructured":"Huang, Y., Hou, X., Lv, F. & Gong, Z. Association of the platelets to high density lipoprotein cholesterol ratio and risk of heart disease events in middle-aged and elderly Chinese population: A retrospective cohort study utilizing the CHARLS database. Rev. Cardiovasc. Med. 26(2), 26403 (2025).","journal-title":"Rev. Cardiovasc. Med."},{"issue":"17","key":"64730_CR8","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.2147\/JIR.S458950","volume":"6","author":"W Wu","year":"2024","unstructured":"Wu, W. et al. Impact of platelet-to-HDL-cholesterol ratio on long-term mortality in coronary artery disease patients with or without type 2 diabetes: Insights from a Chinese multicenter cohort. J. Inflamm. Res. 6(17), 2731\u20132744 (2024).","journal-title":"J. Inflamm. Res."},{"issue":"1","key":"64730_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75453-7","volume":"14","author":"B Wang","year":"2024","unstructured":"Wang, B., Wang, J., Liu, C. & Hu, X. The potential of platelet to high-density lipoprotein cholesterol ratio (PHR) as a novel biomarker for heart failure. Sci. Rep. 14(1), 23283 (2024).","journal-title":"Sci. Rep."},{"key":"64730_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66747-x","volume":"14","author":"L Yan","year":"2024","unstructured":"Yan, L. et al. Association of platelet to high-density lipoprotein cholesterol ratio with hyperuricemia. Sci. Rep. 14, 15641 (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"64730_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00937-4","volume":"22","author":"Y Al Shanableh","year":"2022","unstructured":"Al Shanableh, Y. et al. Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar. BMC Endocr. Disord. 22(1), 21 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"64730_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-20457-1","volume":"24","author":"F Deng","year":"2024","unstructured":"Deng, F. et al. Association between body mass index and serum uric acid: Mediation analysis involving liver enzymes indicators. BMC Public Health 24, 3007 (2024).","journal-title":"BMC Public Health"},{"issue":"1","key":"64730_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01861-9","volume":"22","author":"CF Lu","year":"2017","unstructured":"Lu, C. F. et al. Association between the platelet\/high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: Results from NHANES 2017-2020. Lipids Health Dis. 22(1), 130 (2017).","journal-title":"Lipids Health Dis."},{"key":"64730_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479245","volume":"15","author":"X Hou","year":"2024","unstructured":"Hou, X. et al. Association between platelet-to-high-density lipoprotein cholesterol ratio and future stroke risk: A national cohort study based on CHARLS. Front. Neurol. 15, 1479245 (2024).","journal-title":"Front. Neurol."},{"issue":"1","key":"64730_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02115-y","volume":"23","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Xu, Y. & Xu, Y. The association of the platelet\/high-density lipoprotein cholesterol ratio with self-reported stroke and cardiovascular mortality: A population-based observational study. Lipids Health Dis. 23(1), 121 (2024).","journal-title":"Lipids Health Dis."},{"issue":"5","key":"64730_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321625","volume":"20","author":"C Wu","year":"2025","unstructured":"Wu, C., Hu, Z. & Zhang, P. Association of the platelet-to-high-density lipoprotein cholesterol ratio (PHR) with metabolic syndrome and metabolic overweight\/obesity phenotypes: A study based on the Dryad database. PLoS ONE 20(5), e0321625 (2025).","journal-title":"PLoS ONE"},{"key":"64730_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1373258","volume":"15","author":"AG Casanova","year":"2024","unstructured":"Casanova, A. G., Morales, A. I., Vicente-Vicente, L. & L\u00f3pez-Hern\u00e1ndez, F. J. Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis. Front. Pharmacol. 15, 1373258 (2024).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"64730_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.817150","volume":"23","author":"J Zhu","year":"2022","unstructured":"Zhu, J. et al. The association of hyperuricemia and gout with the risk of cardiovascular diseases: A cohort and Mendelian randomization study in UK biobank. Front. Med. (Lausanne) 23(8), 817150 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"6","key":"64730_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103043","volume":"18","author":"R Chen","year":"2024","unstructured":"Chen, R. et al. Association between urate-lowering therapy initiation and all-cause mortality in patients with type 2 diabetes and asymptomatic hyperuricemia. Diabetes Metab. Syndr. 18(6), 103043 (2024).","journal-title":"Diabetes Metab. Syndr."},{"issue":"4","key":"64730_CR20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.4103\/jfmpc.jfmpc_1833_21","volume":"11","author":"SAM Alqahtani","year":"2022","unstructured":"Alqahtani, S. A. M., Awan, Z. A., Alasmary, M. Y. & Al Amoudi, S. M. Association between serum uric acid with diabetes and other biochemical markers. J. Fam. Med. Prim. Care 11(4), 1401\u20131409 (2022).","journal-title":"J. Fam. Med. Prim. Care"},{"issue":"9","key":"64730_CR21","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/dom.15157","volume":"25","author":"M Banerjee","year":"2023","unstructured":"Banerjee, M., Pal, R., Maisnam, I., Chowdhury, S. & Mukhopadhyay, S. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials. Diabetes Obes. Metab. 25(9), 2697\u20132703 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"64730_CR22","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman, K. J., Greenland, S. & Lash, T. L. Modern epidemiology 3rd ed. (Lippincott Williams & Wilkins, 2008).","edition":"3rd ed"},{"key":"64730_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","volume":"17","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen, J. C., Gluud, C., Wetterslev, J. & Winkel, P. When and how should multiple imputation be used for handling missing data in randomised clinical trials?. BMC Med. Res. Methodol. 17, 162 (2017).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64730-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T13:44:50Z","timestamp":1794231890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64730-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64730"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64730-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The Funding section in the original version of this Article was incorrect. \u201cThis research received no external funding.\u201d now reads: \u201cThe publication fee was provided by the Primary Health Care Corporation (Qatar).\u201d The original Article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26670"}}